Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Marie Cleton-Jansen

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Human Pathology|March 23, 2013
Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneityMarieke A de Graaff, Anne-Marie Cleton-Jansen, Károly Szuhai, et al.
Cancer Genetics|June 12, 2012
Molecular pathology and its diagnostic use in bone tumorsKaroly Szuhai, Anne-Marie Cleton-Jansen, Pancras C W Hogendoorn, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Defining regions of loss of heterozygosity of 16q in breast cancer cell linesDavid F Callen, Joanne Crawford, Cathy Derwas, et al.
Oncotarget|June 6, 2015
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivoJohnny Suijker, Hans J Baelde, Helene Roelofs, et al.
Bioinformatics (Oxford, England)|January 20, 2005
Testing association of a pathway with survival using gene expression dataJelle J Goeman, Jan Oosting, Anne-Marie Cleton-Jansen, et al.
The Journal of Pathology|November 3, 2009
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcomaYongping Cai, Alexander B Mohseny, Marcel Karperien, et al.
The Lancet. Oncology|August 2, 2005
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatmentJudith V M G Bovée, Anne-Marie Cleton-Jansen, Antonie H M Taminiau, et al.
The Journal of Pathology|February 3, 2012
An osteosarcoma zebrafish model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migrationAlexander B Mohseny, Wei Xiao, Ralph Carvalho, et al.
Hematology/Oncology Clinics of North America|October 8, 2013
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcomaJolieke G van Oosterwijk, Jakob K Anninga, Hans Gelderblom, et al.
The Journal of Molecular Diagnostics : JMD|December 21, 2018
Molecular Pathology of Bone TumorsSuk Wai Lam, David G P van IJzendoorn, Anne-Marie Cleton-Jansen, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Human Pathology|March 23, 2013
Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneityMarieke A de Graaff, Anne-Marie Cleton-Jansen, Károly Szuhai, et al.
Cancer Genetics|June 12, 2012
Molecular pathology and its diagnostic use in bone tumorsKaroly Szuhai, Anne-Marie Cleton-Jansen, Pancras C W Hogendoorn, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Defining regions of loss of heterozygosity of 16q in breast cancer cell linesDavid F Callen, Joanne Crawford, Cathy Derwas, et al.
Oncotarget|June 6, 2015
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivoJohnny Suijker, Hans J Baelde, Helene Roelofs, et al.
Bioinformatics (Oxford, England)|January 20, 2005
Testing association of a pathway with survival using gene expression dataJelle J Goeman, Jan Oosting, Anne-Marie Cleton-Jansen, et al.
The Journal of Pathology|November 3, 2009
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcomaYongping Cai, Alexander B Mohseny, Marcel Karperien, et al.
The Lancet. Oncology|August 2, 2005
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatmentJudith V M G Bovée, Anne-Marie Cleton-Jansen, Antonie H M Taminiau, et al.
The Journal of Pathology|February 3, 2012
An osteosarcoma zebrafish model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migrationAlexander B Mohseny, Wei Xiao, Ralph Carvalho, et al.
Hematology/Oncology Clinics of North America|October 8, 2013
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcomaJolieke G van Oosterwijk, Jakob K Anninga, Hans Gelderblom, et al.
The Journal of Molecular Diagnostics : JMD|December 21, 2018
Molecular Pathology of Bone TumorsSuk Wai Lam, David G P van IJzendoorn, Anne-Marie Cleton-Jansen, et al.
Pageof 13